• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Covidien restates Q2 financials ahead of pharma spinout | Wall Street Beat

Covidien restates Q2 financials ahead of pharma spinout | Wall Street Beat

May 20, 2013 By Brad Perriello

MassDevice.com Wall Street Beat

Covidien (NYSE:COV) re-stated its financial results for the fiscal 3rd quarter ended March 29, in anticipation of the planned spinout of its Mallinckrodt pharmaceuticals business next month.

Covidien said the new numbers reflect the pharma unit as a discontinued operation, with COV shareholders slated to receive a tax-free distribution, according to a regulatory filing.

The Mansfield, Mass.-based medical device company previously reported profits of $439 million, or 92¢ per share, on sales of $3.10 billion for the 3 months ended March 29. Profits were down 11.7% compared with Q2 2012, despite sales growth 5.3%.

Sign up to get our free newsletters delivered straight to your inbox

Covidien said its Q2 books now reflect profits of $439 million, or 93¢ per share, on sales of $2.53 billion, according to the filing.

 Digirad proxy war heats up
Digirad Corp. (NSDQ:DRAD) said a dissident investor group led by the Red Oak Fund is looking to set aside the results of the medical device company’s annual stockholders meeting in an effort to get its own nominees on the Digirad board.
Read more

 Siemens details Osram lighting semi-spinout
Siemens (NYSE:SI) said it plans to keep a stake in its Osram lighting subsidiary even after it’s spun out of the German healthcare and industrial giant, retaining a 17.0% share outright and keeping another 2.5% for the Siemens Pension Trust.
Read more

 PositiveID raises $5M in private placement
IBC Funds agreed to buy a $5 million stake in PositiveID (OTC:PSID) over the next 3 years in return for debt financing.
Read more

 Analysts’ ups and downs

  • Abbott (NYSE:ABT): Goldman Sachs upgrades to "buy" from "neutral" rating, raises price target to $44 from $38.
  • Boston Scientific (NYSE:BSX): Wells Fargo upgrades to “outperform” rating.
  • Endologix (NSDQ:ELGX): Canaccord Genuity reiterates "buy" rating, $1.50 price target.
  • Globus Medical (NYSE:GMED): WallachBeth Capital initiates Globus Medical at "buy" rating, $19 price target.
  • Medtronic (NYSE:MDT): Citigroup raises price target to $57; Mizuho increases price target from $52 to $55, "buy" rating.
  • NeuroMetrix (NSDQ:NURO): Zacks cuts to "neutral" rating, $2.10 price target.
  • NuVasive Inc. (NSDQ:NUVA): WallachBeth Capital initiates at "buy" rating, $27 price target.
  • Optos plc (LON:OPTS): Jefferies Group trims price target from £2.80 ($4.30) to £2.40 ($3.69), "buy" rating.
  • Spectranetics (NSDQ:SPNC): Northland Capital Partners downgrades from “outperform” to “market perform” rating; Northland Securities downgrades from an "outperform" to "market perform" rating.
  • Stryker (NYSE:SYK): SunTrust lowers to "neutral" rating, $56 price target; Zacks retains "neutral" rating.
  • Thoratec (NSDQ:THOR): Goldman Sachs downgrades from "buy" to "neutral" rating, lowers price target from $42 to $37.
  • Tornier (NSDQ:TRNX): RBC Capital upgrades from “sector perform” to “outperform” rating.
  • Zimmer (NYSE:ZMH): SunTrust lowers to "neutral" rating, $65 price target.

Filed Under: MassDevice Earnings Roundup, News Well, Pharmaceutical, Wall Street Beat Tagged With: 2013, Covidien, Digirad Corp., PositiveID Corp., Q1, Siemens

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy